<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02319941</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2014-07</org_study_id>
    <nct_id>NCT02319941</nct_id>
  </id_info>
  <brief_title>Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes</brief_title>
  <acronym>OPTIMA</acronym>
  <official_title>Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes; Pharmacodynamics and Pharmacokinetics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>KBM pharm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Low-Dose, Standard-Dose Ticagrelor and Clopidogrel
      for Inhibition of Platelet Reactivity in Patients with Acute Coronary Syndromes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2015</start_date>
  <completion_date type="Actual">March 10, 2017</completion_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P2Y12 reaction units(PRU)</measure>
    <time_frame>8 hours and 30days after first randomized dose</time_frame>
    <description>P2Y12 Reaction Units (PRU) measured by VerifyNow P2Y12 assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage inhibition of platelet aggregation</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8,24 hours and 30 days after first randomized study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregation units(AU), Area Under the Curve(AUC)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8,24 hours and 30 days after first randomized study treatment</time_frame>
    <description>by Multiplate analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of low-responsive patients</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8,24 hours and 30 days after first randomized study treatment</time_frame>
    <description>Low-responsive patients is defined as PRU â‰¥ 235 from VerifyNow P2Y12 and/or percentage of platelet inhibition &lt;15%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacokinetic (PK) profile for Ticagrelor and its metabolite AR-C124910XX</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 10,24 hours after first randomized study treatment</time_frame>
    <description>in terms of maximum concentration (Cmax),time to maximum concentration (tmax) and area under the concentration curve from time zero to infinity (AUC), t1/2, CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE(Major adverse cardiac event)</measure>
    <time_frame>30 days after first randomized study treatment</time_frame>
    <description>Death, Myocardial Infarction, stent thrombosis, stroke,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>30 days after first randomized study treatment</time_frame>
    <description>including bleeding by TIMI/PLATO criteria, dyspnea, bradycardia, syncope,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug tolerance</measure>
    <time_frame>30 days after first randomized study treatment</time_frame>
    <description>Drug tolerance is evaluated as adverse event following discontinuation of drug administration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Low dose ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dose ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>90mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dose clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <arm_group_label>Low dose ticagrelor</arm_group_label>
    <arm_group_label>standard dose ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <arm_group_label>standard dose clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST elevation or non ST elevation acute coronary syndrome patients of chest pain within
             24 hours

        Exclusion Criteria:

          -  Known hypersensitivity to clopidogrel and ticagrelor and aspirin

          -  Treatment with anticoagulants

          -  Exposure to a thrombolytic agent within 24 hours prior to randomization

          -  Use of glycoprotein IIb - IIIa inhibitors at randomization

          -  History of major hemorrhage (intracranial, gastrointestinal, etc.)

          -  clotting disorder and/or bleeding disorder

          -  Any history of Severe renal or hepatic dysfunction

          -  Hematologic disorder including a Hemoglobin less than 10 g/L or a platelet count less
             than 80,000 cells/mm3

          -  Cardiac shock, severe left ventricular dysfunction LVEF less than 30%

          -  Sick sinus syndrome or second degree of av block without permanent pacemaker

          -  No concurrent cytochrome p450 3a inhibitors and enhancers within 2 weeks

          -  Subject has any condition for which, in the opinion of the investigator, participation
             would not be in the best interest of the subject (eg,drug and alcohol abuse, mental
             illness) or that could prevent, limit, or confound the protocol-specified assessments.

          -  Life expectancy of less than 6 months

          -  Pregnancy or lactating

          -  Participation in any drug study in the previous 3 months

          -  Inability to follow the protocol and comply with follow-up requirements or any other
             reason that the investigator feels would place the patient at increased risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2014</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Inhibition of Platelet Reactivity</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

